Table 1.
Basic parameters and therapy of all 117 included patients. * Administrated as part of a clinical study.
| Basis Parameters | |
|---|---|
| Mean age (years ± SD) | 57.2 (±11.9) |
| Female sex (%) | 45 (38.5%) |
| Co-morbidities | |
| Arterial hypertension | 81 (58.3%) |
| Obesity (BMI 30–40) | 57 (41%) |
| Severe obesity (BMI > 40) | 18 (12.9%) |
| Diabetes mellitus II | 48 (35.3%) |
| Chronic lung disease | 27 (19.4%) |
| Hypo/hyperthyroidism | 24 (17.3%) |
| Chronic arterial disease | 19 (13.7%) |
| Chronic renal failure | 9 (6.5%) |
| Chronic heart failure | 7 (5%) |
| Active cancer | 5 (3.6%) |
| Immunosuppression | 4 (2.9%) |
| Days between symptom onset and ICU admission (± SD) | 9.88 (± 6.9) |
| Therapy | |
| Immunomodulating | |
| Dexamethason | 117 (100%) |
| Tocilizumab | 12 (8.6%) |
| Asunercept * | 1 (0.7%) |
| Antiviral therapy | |
| Remdesivir | 51 (43.6%) |
| Camostat | 3 (2.6%) |
| Lopinavir/Ritonavir | 3 (2.6%) |
| Chloroquin/hydroxychloroquin | 1 (0.9%) |
| Parenteral nutrition | 100 (73.5%) |